H.R. 1849 · 114th Congress
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
RoyceSponsor5 cosponsors · 5 D
1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015
What it does: CRS summary · Introduced in House · Apr 16, 2015
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015
Amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to establish and implement a hereditary hemorrhagic telangiectasia (HHT, a genetic vascular bleeding disorder that causes abnormalities of the blood vessels) initiative to improve early detection, screening, and treatment of people who suffer from HHT, focusing on advancing HHT research and increasing physician and public awareness of HHT.
Directs HHS to establish the HHT Coordinating Committee to develop and coordinate implementation of a plan to advance research and understanding of HHT, including by conducting or supporting research at the National Institutes of Health (NIH) and making recommendations regarding NIH research grants relating to HHT.
Requires the Centers for Disease Control and Prevention to carry out activities with respect to HHT, including conducting surveillance and establishing an HHT resource center to provide comprehensive education on and disseminate information about HHT to health professionals, patients, industry, and the public.
Requires the Centers for Medicare & Medicaid Services to award grants for HHT research, including an analysis of health care expenditures associated with untreated HHT and costs associated with preventable medical events among Medicare beneficiaries with HHT.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015
Latest action (Apr 29, 2015): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Apr 16, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.